This is the first study demonstrating coordinated overexpression of CD74 and CTSL and proposing their dual targeting via antibody-drug conjugates (ADCs) to improve outcomes in relapsed or refractory DLBCL. This evidence concerns the gene CD74 and diffuse large B-cell lymphoma.